Subscribe: Biotechnology
http://rss.prnewswire.com/industry/bio
Added By: Feedage Forager Feedage Grade A rated
Language: English
Tags:
announced today  announced  market  nasdaq  new york  new  papers market  prnewswire  research markets  research  today announced  today 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Biotechnology

PR Newswire: Biotechnology



Press Releases from PR Newswire about Biotechnology



Published: Thu, 25 May 2017 20:10:33 EDT

Last Build Date: Thu, 25 May 2017 19:45:00 EDT

 



Eubiotics Market to Reach $9.4 Billion by 2025 - Growing Meat Consumption Coupled with Rising Awareness Regarding Meat Quality - Research and Markets

Thu, 25 May 2017 19:45:00 EDT

(image) DUBLIN, May 25, 2017 /PRNewswire/ -- Research and Markets has announced the addition of the "Eubiotics Market Analysis By Product (Probiotics, Prebiotics, Organic Acids, Essential oils), By Form (Liquid, Solid), By Application (Gut Health, Immunity, Yield), By End-use (Cattle,...



Media Files:
http://photos.prnewswire.com/prnvar/20160330/349511LOGO




Stand Up To Cancer Issues Call for Ideas for $10 Million "Convergence 2.0" Teams to Address Key Questions About the Immune System's Role in Cancer Development and Treatment

Thu, 25 May 2017 17:50:00 EDT

(image) NEW YORK, May 25, 2017 /PRNewswire-USNewswire/ --- Stand Up To Cancer (SU2C) announced that it has issued a $10 million "Convergence 2.0" Call for Ideas seeking new projects, building on its innovative Convergence program. Collaborative teams will develop data/computation-intensive...



Media Files:
https://mma.prnewswire.com/media/356765/su2c_logo_Logo.jpg




Merrimack Announces Management Change

Thu, 25 May 2017 16:30:00 EDT

(image) CAMBRIDGE, Mass., May 25, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the resignation of Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development, effective June 9, 2017. Dr. Al-Wakeel, who has been in his role with Merrimack...



Media Files:
http://www.merrimack.com




Halozyme Therapeutics To Present At Upcoming Healthcare Conferences

Thu, 25 May 2017 16:05:00 EDT

(image) SAN DIEGO, May 25, 2017 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies will be presenting a corporate overview at three upcoming investor conferences. Laurie Stelzer, senior vice president and...



Media Files:
https://mma.prnewswire.com/media/75076/halozyme_therapeutics_logo.jpg




ASAE Launched First Successful Xperience Design Project for Association and Industry Professionals

Thu, 25 May 2017 15:43:00 EDT

(image) WASHINGTON, May 25, 2017 /PRNewswire-USNewswire/ -- ASAE delivered its newest event, Xperience Design Project (XDP), May 23-24, at the Gaylord National® Resort & Convention Center. Over the two days, XDP brought together 1,816 association professionals and industry partners....



Media Files:
https://mma.prnewswire.com/media/198291/american_society_of_association_executives_logo.jpg




The Avoca Quality Consortium (AQC) Unveils a Regulatory Roadmap to ICH E6 R2 at its New York City Quality Summit

Thu, 25 May 2017 15:38:00 EDT

PRINCETON, N.J., May 25, 2017 /PRNewswire/ -- At its annual Summit USA in New York City on May 10-11, 2017, the Avoca Quality Consortium (AQC) released a "Regulatory Roadmap" --  a set of practical guidelines, tools, and documents -- to empower its Members to understand the recently rolled...



The Parenteral Drug Association Connecting Drug Manufacturers, Glass Suppliers to make Manufacturing Great

Thu, 25 May 2017 14:12:00 EDT

(image) BETHESDA, Md., May 25, 2017 /PRNewswire-USNewswire/ -- The Parenteral Drug Association (PDA) is proud to announce a significant initiative to bring together executives, including CEOs and executive vice presidents, from biologic and pharmaceutical manufacturers with glass container and...



Media Files:
https://mma.prnewswire.com/media/170278/parenteral_drug_association_logo.jpg




CDI Labs Expands HuProt™ - The Highest Content Human Proteome Microarray in the World

Thu, 25 May 2017 13:00:00 EDT

(image) MAYAGUEZ, Puerto Rico and BALTIMORE, May 25, 2017 /PRNewswire/ -- CDI Laboratories, Inc. has announced that over 1,000 new recombinant proteins will be added to HuProt™ - its human proteome microarray. With 81% of the human proteome available in a powerful and economical analytical...



Media Files:
http://www.cdi-lab.com




Global Coated Papers Market 2017-2021: Latest Trend Gaining Momentum in the Market is Cost-Effective Biodegradable Packaging - Research and Markets

Thu, 25 May 2017 12:30:00 EDT

(image) DUBLIN, May 25, 2017 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Coated Papers Market 2017-2021" report to their offering. The global coated papers market to grow at a CAGR of 3.43% during the period 2017-2021. Global Coated Papers Market...



Media Files:
http://photos.prnewswire.com/prnvar/20160330/349511LOGO




Saturnino (Nino) Fanlo Joins Human Longevity, Inc. As Chief Financial Officer

Thu, 25 May 2017 12:00:00 EDT

(image) SAN DIEGO, May 25, 2017 /PRNewswire/ -- Human Longevity, Inc. (HLI), the genomics-based, health intelligence company, announced today that Saturnino (Nino) Fanlo will be joining the company as Chief Financial Officer, reporting to CEO Cynthia Collins. Fanlo brings decades of financial...



Media Files:
https://mma.prnewswire.com/media/133259/human_longevity__inc__logo.jpg




PharmaMar and Eczacıbaşı Sign a Licensing Agreement for Aplidin® in Turkey

Thu, 25 May 2017 10:31:00 EDT

(image) MADRID, May 25, 2017 /PRNewswire/ -- PharmaMar (MCE:PHM) has announced today a licensing agreement with Eczacıbaşı Group to commercialize the marine-derived anticancer drug Aplidin® (plitidepsin) in Turkey. Under the terms of the agreement, PharmaMar will receive an upfront payment as...



Media Files:
http://photos.prnewswire.com/prn/20150203/727958-b




Kallyope Inc.'s Ann E. Weber, Ph.D., to Receive Prestigious Perkin Medal

Thu, 25 May 2017 10:00:00 EDT

(image) PHILADELPHIA, May 25, 2017 /PRNewswire/ -- The Society of Chemical Industry (SCI), America Group, announced today that Ann E. Weber, Ph.D., Senior Vice President for Drug Discovery at Kallyope, Inc., has won the 2017 SCI Perkin Medal. This honor recognizes her outstanding work in the field...



Media Files:
https://mma.prnewswire.com/media/515355/SCI_America_Ann_Weber.jpg




Hepatera: Eligibility to PRIME Scheme Granted to Myrcludex B by the European Medicines Agency

Thu, 25 May 2017 09:00:00 EDT

(image) MOSCOW, May 25, 2017 /PRNewswire/ -- MYR GmbH and its development partner Hepatera LLC today announced that the European Medicines Agency (EMA) granted "PRIME eligibility" for Myrcudex B, a first in class entry inhibitor for Hepatitis Delta (D) virus.      (Logo: http://p...



Media Files:
http://photos.prnewswire.com/prn/20140213/668442-b




Capricor Therapeutics Announces Formation of Duchenne Muscular Dystrophy Advisory Board

Thu, 25 May 2017 09:00:00 EDT

(image) LOS ANGELES, May 25, 2017 /PRNewswire/ -- Capricor Therapeutics, Inc. (NASDAQ: CAPR) today announced that, in connection with its growing commitment to the development of CAP-1002 for Duchenne muscular dystrophy (DMD), it has formalized an advisory board composed of key opinion leaders in...



Media Files:
http://capricor.com




SomaGenics Awarded NIH Funding to Develop Novel Cell-free-DNA Liquid Biopsy Platform

Thu, 25 May 2017 08:40:00 EDT

SANTA CRUZ, Calif., May 25, 2017 /PRNewswire/ -- SomaGenics announced the receipt of a Phase I SBIR grant from the National Human Genome Research Institute to support extension of its RealSeq® platform to the sequence analysis of highly fragmented cell-free DNA (cf-DNA). The original...



Luminex Corporation To Present At Jefferies 2017 Global Healthcare Conference

Thu, 25 May 2017 08:30:00 EDT

(image) AUSTIN, Texas, May 25, 2017 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced today that management will present at the Jefferies 2017 Global Healthcare Conference on Thursday, June 8 at 8:30am ET in New York. The investor presentation will be webcast live and may be accesse...



Media Files:
https://mma.prnewswire.com/media/172702/luminex_logo.jpg




Positive Results in Research Delaying Onset of Motor Neurone Disease Announced by Sheffield University and British Artificial Intelligence Firm BenevolentAI

Thu, 25 May 2017 08:00:00 EDT

LONDON, May 25, 2017 /PRNewswire/ -- The Sheffield Institute for Translational Neuroscience (SITraN), part of the University of Sheffield and one of the world's leading centres for research into Motor Neurone Disease, Alzheimer's and Parkinson's Disease, today announced that its...



Phase 1 Safety Study Supports Planned Development of PCM-075 in AML

Thu, 25 May 2017 08:00:00 EDT

(image) SAN DIEGO, May 25, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced summary data from a phase 1 safety study conducted by Nerviano Medical Sciences with PCM-075, a polo-like kinase 1 (PLK1) inhibitor.  This data is suppor...



Media Files:
https://mma.prnewswire.com/media/370471/Trovagene_Logo.jpg




Genomic Health to Present at Jefferies 2017 Healthcare Conference

Thu, 25 May 2017 08:00:00 EDT

(image) REDWOOD CITY, Calif., May 25, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that it will present at the Jefferies 2017 Healthcare Conference in New York City on Tuesday, June 6, 2017 at 4:30 p.m. Eastern Time. To access the live and subsequently archived...



Media Files:
https://mma.prnewswire.com/media/261681/genomic_health__inc__logo.jpg




Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300

Thu, 25 May 2017 08:00:00 EDT

(image) NEWARK, Calif., May 25, 2017 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the company has initiated a Phase 1 clinical study of PTG-300 in normal healthy volunteers.  PTG-300 is an injectable hepcidin mimetic peptide discovered using the company's prop...



Media Files:
https://mma.prnewswire.com/media/333979/protagonist_therapeutics__inc__logo.jpg